ArticleEpilepsia2025
Comparative risk of major health events among individuals prescribed different antiseizure medications following ischemic stroke.
Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Outcomes of patients with post-stroke epilepsy: A scoping review on quality of life, readmissions, costs, seizure recurrence, and medication adherence.Epilepsia open · 2026Review
- Comparative risk of major health events among individuals prescribed different antiseizure medications following ischemic stroke.Epilepsia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to compare the risk of seizure, recurrent stroke, fall or fracture, and mortality in individuals prescribed different antiseizure medications (ASMs) following an ischemic stroke.
methodsWe identified all patients admitted to a Victorian public or private hospital with a principal diagnosis of an incident ischemic stroke between 2013 and 2017 and dispensed an ASM within 12 months of discharge. Cox proportional hazards regression was used to estimate the risk of cause-specific rehospitalization or emergency department visits (seizure, fall or fracture, recurrent stroke) and all-cause mortality over a 2-year period. Inverse probability of treatment weighting was applied to each model to adjust for baseline covariates.
resultsOf 19 601 individuals hospitalized for incident ischemic stroke, 897 initiated ASM treatment within 12 months. More than three quarters were initiated on a non-enzyme-inducing ASM (78.0%). Levetiracetam (41.9%), valproate (28.4%), and carbamazepine (11.4%) were commonly dispensed initial ASMs. Non-enzyme-inducing ASMs demonstrated similar risk of seizure (hazard ratio [HR] = .93, 95% confidence interval [CI] = .63-1.37), fall or fracture (HR = 1.47, 95% CI = .92-2.34), stroke (HR = .83; 95% CI = .52-1.33), and mortality (HR = .96; 95% CI = .69-1.32) compared to enzyme-inducing ASMs. However, when valproate was grouped as a separate class, non-enzyme-inducing ASMs (HR = 1.67, 95% CI = 1.04-2.71) showed higher risk of fall or fracture compared to enzyme-inducing ASMs. SIGNIFICANCE: At a population level, ASMs of different types showed no significant differences in the risk of hospitalization or emergency department presentation for seizure, fall or fracture, stroke, and mortality within 2 years of an incident stroke presentation, suggesting similar short-term health outcomes in a real-world setting. Future research should investigate decision-making around ASM choice for stroke survivors and examine the impact of long-term ASM exposure on health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.